Bergamini Alice, Leone Roberti Maggiore Umberto, Ferrero Simone, Rabaiotti Emanuela, Viganò Riccardo, Petrone Micaela, De Marzi Patrizia, Salvatore Stefano, Candiani Massimo, Mangili Giorgia
Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit , Via Olgettina 58-60, 20132, Milan , Italy.
Expert Opin Investig Drugs. 2015 Mar;24(3):345-62. doi: 10.1517/13543784.2015.999154. Epub 2015 Feb 1.
Pelvic serous carcinomas (PSCs) are a controversial entity, which mostly comprise fallopian tube carcinoma (FTC), primary peritoneal carcinoma (PPC) and serous ovarian carcinoma (OC). Despite incremental attention towards understanding pelvic serous carcinogenesis, the gold standard treatment and survival rates have not substantially changed in these last decades.
This review summarizes and gives a critical overview of the ongoing Phase II trials investigating therapies for PSC.
Several novel molecules have been developed and are currently under investigation for the treatment of PSC, including FTC, PPC and serous OC. The trend of novel targeted agents is one towards individualized, tailored therapy, based on the molecular and biological differences that characterize tumors that seem similar based solely on histological analysis. The task of developing new molecules is particularly difficult for PSC, given the recurrent development of new patterns of drug resistance. However, even if current research is focused towards identifying the best treatments for each woman with a molecularly defined disease, a deeper knowledge of the molecular biology and genetics underlying FTC and its relation as a precursor of PSC is needed.
盆腔浆液性癌（PSC）是一个存在争议的实体，主要包括输卵管癌（FTC）、原发性腹膜癌（PPC）和浆液性卵巢癌（OC）。尽管在理解盆腔浆液性癌发生方面受到越来越多的关注，但在过去几十年中，其金标准治疗方法和生存率并未发生实质性变化。
本综述总结并批判性地概述了正在进行的针对PSC治疗的II期试验。
已经开发了几种新型分子，目前正在研究用于治疗PSC，包括FTC、PPC和浆液性OC。新型靶向药物的趋势是基于仅通过组织学分析看似相似的肿瘤所具有的分子和生物学差异，走向个体化、量身定制的治疗。鉴于新的耐药模式不断出现，开发新分子的任务对PSC来说尤其困难。然而，即使目前的研究重点是为每一位患有分子明确疾病的女性确定最佳治疗方法，也需要更深入地了解FTC的分子生物学和遗传学及其作为PSC前体的关系。
